Tesamorelin is a growth hormone-releasing hormone analogue investigated for stimulation of endogenous growth hormone and changes in visceral adipose tissue. Clinical studies of pharmaceutical tesamorelin concern defined populations, including HIV-associated abdominal fat accumulation.

Key research interests

• GHRH receptor signaling

• Growth hormone and IGF-1 responses

• Visceral adipose tissue measures

Not for human or veterinary use

Sermorelin acetate is the acetate salt of a peptide corresponding to the active 1–29 segment of growth hormone-releasing hormone. It is used in research on pituitary GHRH receptor activity and growth hormone secretion. Product identity, salt form, and laboratory formulation matter when comparing results across studies.

Key research interests

• Pituitary GHRH receptor activity

• Growth hormone secretion

• Endocrine response characterization

Not for human or veterinary use

The listing Kisspetin-10 appears to refer to kisspeptin-10, a peptide involved in reproductive hormone regulation. Human studies have examined stimulation of GnRH-related pathways and changes in luteinizing hormone, with responses differing by sex and physiological context. Confirm the identity before publishing the normalized product name.

Key research interests

• GnRH and gonadotropin signaling

• Luteinizing hormone responses

• Reproductive endocrine physiology

Not for human or veterinary use

Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor and stimulates growth hormone release.

Key research interests

• Ghrelin receptor signaling

• Growth hormone release

• Endocrine pharmacokinetics

Not for human or veterinary use

The name CJC-1295 without DAC is commonly used for modified GRF 1–29, a shorter-acting growth hormone-releasing hormone analogue. Research interests include pulsatile endocrine responses and GHRH receptor activity.

Key research interests

• GHRH receptor signaling

• Pulsatile growth hormone responses

• Sequence and exposure characterization

Not for human or veterinary use

CJC-1295 with DAC is a growth hormone-releasing hormone analogue incorporating a drug affinity complex intended to extend exposure through albumin binding. Human studies reported prolonged increases in growth hormone and IGF-1. Research centers on endocrine signaling and exposure duration; hormone changes alone do not establish muscle, recovery, or anti-aging outcomes.

Key research interests

• Growth hormone and IGF-1 signaling

• Albumin binding and prolonged exposure

• Endocrine response patterns

Not for human or veterinary use